The BCL2L2 Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the BCL2L2 gene in Jurkat cells. This loss-of-function model yields a heterogeneous pool of cells lacking functional BCL-W protein, enabling studies of apoptosis and T cell survival without clonal selection. The polyclonal format preserves genetic diversity and facilitates investigation of BCL-2 family interactions and mitochondrial apoptotic signaling in a human T lymphocyte context.
Jurkat cells are an immortalized human T lymphocyte line derived from a T cell leukemia patient. Widely used to study T cell signaling, activation, and apoptosis, they feature well-characterized pathways and are amenable to genetic manipulation. Jurkat cells recapitulate adaptive immune responses and cell-mediated immunity, making them ideal for examining lymphocyte survival determinants. They have been instrumental in elucidating BCL-2 family control of mitochondrial outer membrane permeabilization and caspase activation in cancer and autoimmunity.
BCL2L2 encodes BCL-W, an anti-apoptotic BCL-2 family protein that inhibits the intrinsic apoptotic pathway. BCL-W binds pro-apoptotic effectors BAX and BAK, preventing their oligomerization, mitochondrial outer membrane permeabilization, and cytochrome c release. This blocks apoptosome formation with APAF1 and activation of caspase-9 and caspase-3. BCL-W is regulated by upstream signals including IL-2, IL-7, PI3K/AKT, and NF-??B, and interacts with BCL-2 family members BAD, BID, BIM, and BCL-XL, integrating survival cues.
In Jurkat T lymphocytes, BCL2L2 knockout sensitizes cells to mitochondria-dependent apoptosis, modeling how loss of BCL-W protection affects leukemic T cells. Originating from a leukemia patient, this knockout is relevant for studying apoptosis resistance in lymphoid malignancies and may reveal therapeutic vulnerabilities in BCL-2-dependent cancers. The model also enables investigation of cytokine survival signaling convergence on mitochondrial apoptosis, offering insights into T cell homeostasis and autoimmune diseases where defective apoptosis promotes lymphocyte accumulation.
Researchers can utilize BCL2L2 knockout Jurkat polyclonal cells in a range of functional assays. Apoptosis induction upon loss of BCL-W can be quantified by Annexin V staining with flow cytometry and by measuring caspase-9 and caspase-3 activities. Co-immunoprecipitation experiments detect altered interactions among BCL-2 family proteins, while western blotting provides expression profiling. Cell viability assays under cytokine deprivation or chemotherapeutic treatment reveal the contribution of BCL-W to survival. These applications support research into T cell leukemia, lymphoma, autoimmune disorders, and the development of apoptosis-targeted cancer therapies. For further technical information, please contact Ascent Research.
